Last reviewed · How we verify
Jinfukang oral liquid
Jinfukang oral liquid, marketed by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., is an established product in the Chinese pharmaceutical market. The key composition patent for Jinfukang is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. However, the lack of detailed primary indication and trial results data poses a significant risk in assessing its long-term market competitiveness and regulatory compliance.
At a glance
| Generic name | Jinfukang oral liquid |
|---|---|
| Also known as | Jinfukang koufuye |
| Sponsor | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC (PHASE4)
- the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs (PHASE1)
- Curative Study of Chinese Traditional Medicine to Treat Lung Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: